RBC Capital has raised its price target for Compass Pathways (NASDAQ:CMPS) to $22 from $21 and kept an Outperform rating on the stock. The move came as the company disclosed results from a second successful Phase III trial along with longer-term follow-up findings from the 005 study.
Compass's shares, which are trading at $7.63 according to InvestingPro data, have experienced notable volatility, including a 20.92% gain in the past week. InvestingPro also assigns a Fair Value assessment that suggests the current market capitalization of $732.61 million may represent a modest undervaluation relative to the analyst view.
RBC Capital analyst Leonid Timashev commented that the data presented no red flags. According to the analyst, the synthetic psilocybin formulation COMP360 showed effectiveness in patients with treatment-resistant depression and, in responders, produced durable effects extending up to six months following one or two doses. Timashev highlighted the treatment's uncomplicated dosing regimen and what he described as a clean safety profile.
RBC's analysis interprets the clinical dataset as supportive of a path toward regulatory approval and commercialization by 2027 and calculates an addressable opportunity greater than $1.6 billion for the therapy. The firm has also raised its internal probability of success for the drug candidate and indicated that it would be buyers into strength.
Analyst targets for CMPS span a wide range, from $8 to $40, and investors are awaiting earnings results expected in eight days. InvestingPro supplements these data points with 11 additional tips and full research reports on Compass Pathways to provide more detailed financial and growth analysis.
In separate corporate activity, Compass Pathways has proposed a public offering of $150 million in American Depositary Shares (ADSs), which includes an option for underwriters to purchase an extra $22.5 million of ADSs. The securities package also contemplates the issuance of pre-funded warrants for certain institutional investors.
The company reported highly statistically significant findings from its second Phase 3 trial for COMP360, named COMP006, which met its primary endpoint with a meaningful reduction in depression symptom severity versus control. Compass plans to publish additional clinical information from its ongoing Phase 3 trials: Parts A and B of COMP005 and Part A of COMP006. Those data are scheduled for release on February 17 at 6:30 am ET.
Separately reported commentary within the coverage noted that RBC Capital had previously raised its price target to $21 from $16 while maintaining an Outperform rating following positive insights from a recent Psychedelics Symposium. These multiple mentions of updated price targets and continuing positive trial developments underline the evolving analytical and market response to Compass Pathways' clinical progress and financing plans.
Overall, the combination of positive Phase III and follow-up data, an increased probability of commercial success in RBC's model, a proposed equity offering, and imminent additional data releases has generated renewed attention from analysts and investors. The company and its COMP360 candidate remain focal points for market participants tracking mental health innovation, biotech development pathways, and capital markets activity tied to clinical-stage therapeutics.